CLPT Expands Into Robotic System Supporting Cell and Gene Therapies
ClearPoint's new Robotic Neuro-Navigation System merges proven software with KUKA robotics to boost precision in cell and gene therapy delivery.
Zacks·6h ago
More News
GEHC Inks License Agreement With Lantheus for Prostate Imaging Agent
GE HealthCare strengthens its radiopharmaceutical portfolio by licensing Lantheus' PSMA PET imaging agent, PYLARIFY, for commercialization in Japan.
Zacks·10d ago
Masimo Completes Divestment of Consumer Audio Business to HARMAN
MASI completes sale of Sound United to HARMAN, sharpening focus on core healthcare, boosting margins, and funding buybacks.
Zacks·11d ago
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Zacks·13d ago
Are Medical Stocks Lagging AxoGen (AXGN) This Year?
Here is how AxoGen (AXGN) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Zacks·24d ago
Does AxoGen (AXGN) Have the Potential to Rally 53.1% as Wall Street Analysts Expect?
The mean of analysts' price targets for AxoGen (AXGN) points to a 53.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·1mo ago
Why Is Axogen Stock Down 15% In Pre-Market Today?
The stock tumbled after the company announced that the U.S. FDA pushed the date of the decision regarding approval for Avance Nerve Graft by three months.
Stocktwits·1mo ago
Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 76.4% in AxoGen (AXGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·2mo ago
AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of +100.00% and +7.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
Waters (WAT) Surpasses Q2 Earnings and Revenue Estimates
Waters (WAT) delivered earnings and revenue surprises of +0.68% and +3.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?